Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gigamon (GIMO) to Report Q2 Earnings: What's in the Cards?

We expect fiscal second-quarter earnings of Gigamon (GIMO) to gain traction from product launches.

    DST Systems (DST) Q2 Earnings: Is a Surprise in Store?

    DST Systems' (DST) continued share buybacks and dividend payments are likely to remain tailwinds in Q2.

      Xilinx (XLNX) to Post Q1 Earnings: What's in the Cards?

      Xilinx's (XLNX) growing demand for 28-nm, 20-nm and 16-nm nodes is likely fuel Q1 Earnings. The company's product launches should further aid revenues.

        Why Vertex Pharmaceuticals (VRTX) Might Surprise This Earnings Season

        Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

          What's in the Cards for Exelixis (EXEL) in Q2 Earnings?

          Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.

            Is Celgene (CELG) Poised For a Beat This Earnings Season?

            Celgene Corporation (CELG) is likely to beat on earnings estimates when it reports results on July 27 on the back of growth in Revlimid driven by share gains in important markets.

              Zacks.com featured highlights: Vertex Pharmaceuticals, AGCO, Owens Corning, Five9 and Axcelis Technologies

              Zacks.com featured highlights: Vertex Pharmaceuticals, AGCO, Owens Corning, Five9 and Axcelis Technologies

                Equifax (EFX) to Post Q2 Earnings: What's in the Cards?

                Equifax's (EFX) strategic initiatives for product innovation, acquisitions and continuous share gains in North America, are likely to act as tailwinds in Q2.

                  What's in the Offing for F5 Networks (FFIV) in Q3 Earnings?

                  F5 Networks Inc.'s (FFIV) GBB pricing strategy and its BIG-IQ platform will remain tailwinds in Q3.

                    Top Ranked Momentum Stocks to Buy for July 24th

                    Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 24th:

                      Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?

                      Impressive performance of Vertex Pharmaceuticals' (VRTX) cystic fibrosis drugs Kalydeco and Orkambi may drive the stock to an earnings beat in Q2.

                        What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?

                        Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.

                          Vertex Pharma, A10 Networks, Microsoft, Visa and eBay highlighted as Zacks Bull and Bear of the Day

                          Vertex Pharma, A10 Networks, Microsoft, Visa and eBay highlighted as Zacks Bull and Bear of the Day

                            Can Merck (MRK) Pull Off a Surprise this Earnings Season?

                            Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.

                              Seres Therapeutics (MCRB) Catches Eye: Stock Gains 9.2%

                              Seres Therapeutics, Inc. (MCRB) shares rose a little above 9% in the last trading session.

                                Brian Hamilton headshot

                                Bull of the Day: Vertex Pharma (VRTX)

                                Positive trial results are viewed as a game changer for the treatment of CF

                                  Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View

                                  Increase in Exondys 51 sales led Sarepta (SRPT) to post a narrower-than-expected loss in the second quarter of 2017.

                                    Company News for July 20, 2017

                                    Companies In The News are: VRTX,DISCA,UAL,CCI

                                      Is Gilead (GILD) Poised for a Beat This Earnings Season?

                                      Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.

                                        Megan Sanks headshot

                                        Here's Why Vertex Pharmaceuticals (VRTX) Soared Today

                                        Shares of Vertex Pharmaceuticals Incorporated (VRTX) soared 24% in morning trading on Wednesday after the company released positive results for its cystic fibrosis treatments.

                                          Vertex (VRTX) Triple Combination CF Studies Data Positive

                                          Vertex announced positive data from three studies evaluating three different triple combination regimens. These demonstrated pronounced improvements in lung function in CF patients.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs

                                            Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.

                                              Mark Vickery headshot

                                              Top Stock Reports for Apple, JPMorgan & Celgene

                                              Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and Celgene (CELG).

                                                The Zacks Analyst Blog Highlights: Crescent Point Energy, Vertex Pharmaceuticals, SodaStream International, Commercial Vehicle Group and Melco Crown Entertainment

                                                The Zacks Analyst Blog Highlights: Crescent Point Energy, Vertex Pharmaceuticals, SodaStream International, Commercial Vehicle Group and Melco Crown Entertainment

                                                  Can Novartis (NVS) Spring a Surprise This Earnings Season?

                                                  Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.